Medica RCP |Increlex | Indications | Side Effects | Composition | Route | all.price

Do You Know

03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *

Products » Items » Increlex

Increlex :
Type	TAU
Originator	B
Agent	Droguerie de l'Union
Distributor	Droguerie de l'Union
Laboratory	Ipsen Pharma
Manufacturer	Ipsen Pharma Biotech
Origin	France
ATC	H01AC03

Increlex :

Subcutaneous

Increlex :

H Systemic hormonal preparations, excluding sex hormones and insulins

H01 Pituitary and hypothalamic hormones and analogues

H01A Anterior pituitary lobe hormones and analogues

H01AC Somatropin and somatropin agonists

H01AC03 Mecasermin

Increlex :

Mecasermin : 40mg

Increlex :

Children : Growth failure 0.08mg/kg

Increlex :

Benzyl alcohol* Contraindicated in children under 3 years old

◼

Glacial acetic acid (E260)

Polysorbate 20 Emulsifying Agents

Sodium acetate

Sodium chloride

Water for injections

* Excipient with known effect

Hazard Level
◼ Major
◼ Moderate
◼ Minor
◼ Safe

Increlex :

Revision Date : 27/05/2015

Frequency	Percentage
Very Common	≥ 1/10
Common	≥ 1/100 - < 1/10
Uncommon	≥ 1/1,000 - < 1/100
Rare	≥ 1/10,000 - < 1/1,000
Very Rare	< 1/10,000
Unknown	Cannot be Estimated

Effect	Frequency
Abdominal pain	Common
Abdominal pain upper	Very Common
Adenoidal hypertrophy	Common
Alopecia	Not known
Anaphylaxis	Not known
Angioedema (Angioneurotic oedema) (Quincke oedema)	Not known
Arthralgia (Pain joint) (Joint ache)	Very Common
Benign intracranial hypertension	Uncommon
Cardiac murmur	Common
Cardiomegaly	Uncommon
Convulsion	Common
Depression	Uncommon
Dizziness	Common
Drug specific antibody present	Not known
Dyspnoea (dyspnea)	Common
Ear tube insertion	Common
Gynecomastia (Gynaecomastia)	Common
Hair texture abnormal	Common
Headache	Very Common
Hyperglycaemia	Common
Hypersensitivity	Not known
Hypoacusis	Common
Hypoglycaemia	Very Common
Hypoglycaemic seizure	Common
Injection site bruising	Very Common
Injection site erythema	Common
Injection site haematoma	Common
Injection site haemorrhage	Common
Injection site hypertrophy	Very Common
Injection site induration	Common
Injection site irritation	Common
Injection site pain	Common
Injection site pruritus	Not known
Injection site rash	Uncommon
Injection site reaction	Common
Injection site swelling	Common
Injection site urticaria	Not known
Lipohypertrophy	Uncommon
Melanocytic naevus	Common
Middle ear effusion	Common
Mitral valve incompetence	Uncommon
Myalgia	Common
Nervousness	Uncommon
Otalgia (Earache) (Ear pain)	Common
Otitis media	Very Common
Pain in extremity (Pain in limb)	Very Common
Papilloedema	Common
Scoliosis	Common
Skin hypertrophy	Common
Sleep apnoea syndrome	Common
Snoring	Common
Tachycardia	Common
Thymus enlargement	Common
Tonsillar hypertrophy	Common
Tremor	Common
Tricuspid valve incompetence	Uncommon
Urticaria generalised	Not known
Ventricular hypertrophy	Uncommon
Vomiting	Very Common
Weight increased (weight gain)	Uncommon

Increlex :

Abu Dhabi

Belgium

Cyprus

Denmark

France

Ireland

Norway

The Netherlands

Coming Very Soon

Increlex
MEDICA Code 2060018

Different Units By MoH Code

Increlex MoH 2060018 :

Form Powder for solution for injection

Packaging Bottle

Package Size 1x4ml

Strength 40mg

Stratum N/A

NSSF ✘

Quarantine ✘

Price Comparison

You have to register to view this info

Note

You have to register to view this info

Note

Prices are provided in Dollar ($)

You have to register to view this info

Visitors Count: 30971257

Form	Powder for solution for injection
Packaging	Bottle
Package Size	1x4ml
Strength	40mg
Stratum	N/A
NSSF	✘
Quarantine	✘